Primary Endpoint, ADCS-ADL Did Not Reach Significance At Week 48
28/07/2024 22:05
July 28 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* RESULTS FROM ANAVEX LIFE SCIENCES LANDMARK PHASE IIB/III
TRIAL
OF BLARCAMESINE PRESENTED AT ALZHEIMER'S ASSOCIATION CONFERENCE
* ANAVEX LIFE SCIENCES: FUNCTIONAL CO-PRIMARY ENDPOINT,
ADCS-ADL
DID NOT REACH SIGNIFICANCE AT WEEK 48
Source text for Eikon: ID:nGNXXKzTR
Further company coverage: AVXL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anavex Life Sciences
See all newsBrief: Anavex Provides Corporate Update, Announces Completion Of Clinical Conduct Of Adme And Ddi Clinical Studies
Brief: Anavex Receives FDA Clearance Of Its Ind Application For Blarcamesine In Fragile X Syndrome
Brief: Glass Lewis Recommends Anavex Stockholders To Vote For PVG’s Director Nominees
Brief: PVG Calls For Replacing Anavex Board, Hiring "Experienced" CEO
Brief: Pvg Asset Management- Nominates Six Director Candidates For Anavex Board